PharmaEngine, Inc. (TPEX:4162)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
64.60
+0.10 (0.16%)
Feb 11, 2026, 1:30 PM CST
Market Cap9.28B -32.1%
Revenue (ttm)2.51B +201.1%
Net Income1.67B +352.5%
EPS11.63 +352.7%
Shares Out143.68M
PE Ratio5.55
Forward PE23.86
Dividend6.00 (9.30%)
Ex-Dividend DateAug 13, 2025
Volume374,851
Average Volume616,515
Open65.00
Previous Close64.50
Day's Range64.10 - 65.00
52-Week Range62.30 - 121.50
Beta0.17
RSI36.81
Earnings DateMar 13, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 44
Stock Exchange Taipei Exchange
Ticker Symbol 4162
Full Company Profile

Financial Performance

In 2024, PharmaEngine's revenue was 2.52 billion, an increase of 228.70% compared to the previous year's 767.67 million. Earnings were 1.75 billion, an increase of 537.55%.

Financial Statements